3 completed, 2 terminated, 1 active not recruiting, 1 withdrawn. 3 Phase 2, 2 Not applicable, 1 Phase 3, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 1, Terminated 1, Withdrawn 1 |
| Not applicable | 2 | Active not recruiting 1, Terminated 1 |
| Phase 3 | 1 | Completed 1 |
| Phase 4 | 1 | Completed 1 |
Follow Treatment Resistant Major Depressive Disorder: new trials by email Literature Review of Treatment Resistant Major Depressive Disorder trials Research Report on Treatment Resistant Major Depressive Disorder
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Repeated Intranasal Esketamine Plus Almond Therapy in Participants With Treatment Resistant Depressive Disorder - 3 Month Extension Study Almond Therapy, Intranasal ketamine (Esketamine), Treatment as Usual - Treatment Resistant Major Depressive Disorder | Phase 2 | Withdrawn | Zylorion Health | 2023-01-15 | 2022-11-15 | |
| Repeated Intranasal Esketamine Plus Almond Therapy in Patients With Treatment Resistant Depression Psychotherapy, Treatment as Usual, Intranasal Ketamine (esketamine) - Treatment Resistant Major Depressive Disorder | Phase 2 | Terminated | Zylorion Health | 6 | 2022-10-13 | 2023-03-24 |
| Remotely Programmed Deep Brain Stimulation of the Bilateral Habenula for Treatment- Resistant Major Depression: An Open Label Pilot Trial Bilateral surgical implantation of DBS system to Habeluna, Follow-up Period - Treatment Resistant Major Depressive Disorder | Not applicable | Terminated | Ruijin Hospital | 2 | 2017-07-24 | 2019-11-29 |
| Comparative Effectiveness Research Trial for Antidepressant Incomplete and Non-responders With TRD Aripiprazole, Repetitive transcranial magnetic stimulation (rTMS), Venlafaxine XR - Treatment Resistant Major Depressive Disorder | Phase 4 | Completed | Massachusetts General Hospital | 278 | 2017-07-13 | 2026-07-09 |
| A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Treatment Resistant Major Depressive Disorder AXS-05, Bupropion - Treatment Resistant Major Depressive Disorder | Phase 3 | Completed | Axsome Therapeutics, Inc. | 312 | 2016-03-01 | 2021-03-24 |
| DBS of the Lateral Habenula in Treatment-Resistant Depression Activa Tremor Control Sys (DBS Implant), Randomized, staggered withdrawal phase - Treatment Resistant Major Depressive Disorder | Not applicable | Active not recruiting | Wayne Goodman MD | 6 | 2013-02-01 | 2025-11-28 |
| This is a Study to Determine the Antidepressant Effects of AZD6765 AZD6765, Placebo to AZD6765 - Treatment Resistant Major Depressive Disorder | Phase 2 | Completed | AstraZeneca | 22 | 2009-12-01 | 2014-10-21 |
Depression (2) · Depressive Disorder, Major (2) · Depressive Disorder, Treatment-Resistant (2)
Behavior (2) · Behavioral Symptoms (2) · Depressive Disorder (2) · Mental Disorders (2) · Mood Disorders (2)
Esketamine (2) · Therapeutics (2) · AZD6765 (1) · Aripiprazole (1) · Bupropion (1) · Deep Brain Stimulation (1) · Psychotherapy (1) · Random Allocation (1) · Transcranial Magnetic Stimulation (1) · Venlafaxine Hydrochloride (1)
Zylorion Health (2) · AstraZeneca (1) · Axsome Therapeutics, Inc. (1) · Massachusetts General Hospital (1) · Ruijin Hospital (1) · Wayne Goodman MD (1)
United States (4) · Canada (2) · China (1)
Pierre Chue, MBBCh (2) · Carlos A Zarate, MD (1) · Wayne K Goodman, MD (1)
PMID 23206319, PMID 27914292, PMID 34510411, PMID 38454079, PMID 40801757